Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copanlisib + cetuximab
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Copanlisib + cetuximab is a combination therapy being investigated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Copanlisib is an intravenous, pan-class I PI3K inhibitor with predominant activity against the PI3Kα and PI3Kδ isoforms, developed by Bayer. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The combination is specifically being evaluated in patients whose tumors harbor PI3KCA mutations, PI3KCA amplification, or PTEN loss, as these alterations are common in HNSCC and contribute to resistance against EGFR inhibitors. By simultaneously blocking the EGFR and PI3K pathways, the regimen aims to restore sensitivity to treatment and improve outcomes in patients who have progressed after platinum-based chemotherapy.
- Other names
- copanlisib and cetuximab combinationcopanlisib plus cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on copanlisib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copanlisib + cetuximab.